The Bar Is Raised At ASCO For ADC Developers

 
• By Lucie Ellis-Taitt

Multiple early-stage data presentations at ASCO for antibody-drug conjugates in solid tumors highlight that clinical data success measures need to be tougher to push developers towards treatment-altering breakthroughs.

Mountain
ADC developers need to aim higher with early stage cancer therapies

More from Clinical Trials

More from R&D